AVADEL PHARMACEUTICALS (AVDL)
IE00BDGMC594 - Common Stock
We assign a fundamental rating of 4 out of 10 to AVDL. AVDL was compared to 194 industry peers in the Pharmaceuticals industry. While AVDL seems to be doing ok healthwise, there are quite some concerns on its profitability. AVDL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AVDL had negative earnings in the past year.
In the past year AVDL has reported a negative cash flow from operations.
In the past 5 years AVDL reported 4 times negative net income.
In the past 5 years AVDL always reported negative operating cash flow.
1.2 Ratios
AVDL has a Return On Assets of -45.86%. This is comparable to the rest of the industry: AVDL outperforms 40.63% of its industry peers.
The Return On Equity of AVDL (-97.20%) is worse than 60.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.86% | ||
| ROE | -97.2% | ||
| ROIC | N/A |
ROA(3y)-77.37%
ROA(5y)-50.36%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of AVDL (91.92%) is better than 96.88% of its industry peers.
In the last couple of years the Gross Margin of AVDL has grown nicely.
AVDL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.29%
GM growth 5Y3.15%
2. Health
2.1 Basic Checks
AVDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
AVDL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AVDL has more shares outstanding
There is no outstanding debt for AVDL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
AVDL has an Altman-Z score of 0.78. This is a bad value and indicates that AVDL is not financially healthy and even has some risk of bankruptcy.
AVDL has a Altman-Z score (0.78) which is comparable to the rest of the industry.
AVDL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.78 |
ROIC/WACCN/A
WACC7.18%
2.3 Liquidity
A Current Ratio of 2.97 indicates that AVDL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.97, AVDL is in line with its industry, outperforming 49.48% of the companies in the same industry.
AVDL has a Quick Ratio of 2.60. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.60, AVDL perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.97 | ||
| Quick Ratio | 2.6 |
3. Growth
3.1 Past
AVDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.14%, which is quite impressive.
AVDL shows a strong growth in Revenue. In the last year, the Revenue has grown by 1523.50%.
AVDL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -22.99% yearly.
EPS 1Y (TTM)65.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.68%
Revenue 1Y (TTM)1523.5%
Revenue growth 3Y7.78%
Revenue growth 5Y-22.99%
Sales Q2Q%613.29%
3.2 Future
AVDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.72% yearly.
The Revenue is expected to grow by 81.02% on average over the next years. This is a very strong growth
EPS Next Y76.8%
EPS Next 2Y53.17%
EPS Next 3Y41.48%
EPS Next 5Y27.72%
Revenue Next Year548.18%
Revenue Next 2Y234.95%
Revenue Next 3Y146.42%
Revenue Next 5Y81.02%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AVDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 17.24, which indicates a rather expensive current valuation of AVDL.
AVDL's Price/Forward Earnings ratio is rather cheap when compared to the industry. AVDL is cheaper than 81.77% of the companies in the same industry.
AVDL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.82, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 17.24 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AVDL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AVDL's earnings are expected to grow with 41.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.17%
EPS Next 3Y41.48%
5. Dividend
5.1 Amount
No dividends for AVDL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AVADEL PHARMACEUTICALS
NASDAQ:AVDL (11/22/2024, 2:11:46 PM)
11.99
+0.33 (+2.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.09B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 17.24 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.86% | ||
| ROE | -97.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.92% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.97 | ||
| Quick Ratio | 2.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)65.14%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y76.8%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1523.5%
Revenue growth 3Y7.78%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y